Bristol Myers Squibb shares preliminary Phase 3 open‑label data for KarXT in Alzheimer’s disease psychosis

Bristol Myers Squibb presented early results from two open‑label parts of its Phase 3 ADEPT program evaluating KarXT for psychosis associated with Alzheimer’s disease. In the 12‑week ADEPT‑1 lead‑in, 320 patients were enrolled and 273 completed, showing a mean 12.0‑point drop on the NPI‑C hallucinations‑delusions scale. The 52‑week ADEPT‑3 extension enrolled 401 patients, 273 completed, and recorded a mean 5.1‑point reduction on the same scale. Both studies reported safety profiles consistent with prior experience.

The company said the findings are encouraging as it awaits results from the double‑blind portions of the ADEPT trials, which could shape future regulatory approval for an unmet Alzheimer’s psychosis indication. Investors will watch the upcoming blinded data for potential impact on KarXT’s market potential.

  • 1ADEPT‑1 enrolled 320 participants, of whom 273 (85.3%) completed the 12‑week open‑label period.
  • 2Mean reduction of 12.0 points from a baseline of 14.4 on the NPI‑C hallucinations‑delusions scale was observed in ADEPT‑1.
  • 3Treatment‑emergent adverse events occurred in 56.6% of ADEPT‑1 participants, serious TEAEs in 5.0%, and discontinuations due to TEAEs in 4.4%.
  • 4ADEPT‑3 enrolled 401 participants, of whom 273 (68.1%) completed the 52‑week extension.
  • 5Mean reduction of 5.1 points from an open‑label baseline of 8.9 on the NPI‑C hallucinations‑delusions scale was observed in ADEPT‑3.
  • 6Treatment‑emergent adverse events occurred in 65.1% of ADEPT‑3 participants, serious TEAEs in 7.7%, and discontinuations due to TEAEs in 4.7%.

Sources